Blog

From October 31st to November 2nd, 2024, the Spobiotic Research Center, ANABIO R&D, participated in the 25th National Pediatrics Conference in Hue City entiled “From Science to Policy and Practice.” The conference is a prestigious scientific forum, gathering leading experts from Vietnam and abroad to share the latest advancements in pediatrics.

At the conference, Dr. Dang Thuy Ha, MD, PhD, Deputy Head of the Gastroenterology Department at the National Children’s Hospital, presented the report “Characteristics of Gut Microbiota and Treatment Outcomes for Persistent Diarrhea at the National Children’s Hospital.” This research was conducted in collaboration between the doctors of the National Children’s Hospital and the Spobiotic Research Center, ANABIO R&D. The report highlighted positive results in shortening treatment duration and increasing the effectiveness of managing persistent diarrhea in children by combining conventional treatments with water-based probiotic Bacillus spore products such as LiveSpo CLAUSY (Bacillus clausii, 2 billion CFU/5 mL) and LiveSpo DIA30 (Bacillus subtilis, Bacillus clausii, Bacillus coagulans, 5 billion CFU/5 mL). These products have been recognized as promising solutions in treating prolonged diarrhea, contributing to reduced antibiotic use in children. Findings from the study were published in Nature Scientific Reports in March 2024, providing further scientific support for optimizing treatment protocols for children with prolonged diarrhea.

The conference also featured participation from numerous health administrators and leaders from healthcare facilities across the country, offering an opportunity for a comprehensive evaluation of issues in pediatrics to develop and refine appropriate health policies. Contributions at the conference not only aim to enhance the quality of child healthcare but also lay the foundation for sustainable development of Vietnam’s healthcare sector in pediatrics. This information serves as valuable updates for scientists of the Spobiotic Research Center, ANABIO R&D, to generate ideas for probiotic product development, aligned with the mission of “a future without antibiotics.”

Recently, the Spobiotic Research Center collaborated with Hanoi Medical University to conduct the study titled “Efficacy of Saline Solution and Probiotic Products in Preventing Upper Respiratory Infections in Children Aged 2 to 6 in Son Tay Town, Hanoi, 2024.” This study, led by Assoc. Prof. Dr. Nguyen Thi Hoai Thu, was reviewed and accepted by the Institute for Preventive Medicine and Public Health, Hanoi Medical University. This collaboration marks a significant advancement in probiotic research, aiming to support respiratory disease prevention in young children and reduce antibiotic dependency, especially in the field of preventive healthcare

This is the first study in the world to demonstrate the safety and superior effectiveness of nasal spray probiotics containing Bacillus spores (LiveSpo^® NAVAX and LiveSpo^® NAVAX KIDS) in preventing and reducing the recurrence of upper respiratory tract infections in children. Clinical trial results revealed that after 14 and 28 days of use, LiveSpo^® NAVAX and LiveSpo^® NAVAX KIDS effectively reduced typical respiratory symptoms-such as runny nose, sinusitis, hoarseness, pharyngitis, and tonsillitis compared to baseline and in comparison, with saline solution.

A key highlight of this research is the outstanding ability of LiveSpo^® NAVAX and LiveSpo^® NAVAX KIDS to prevent pathogenic viruses and bacteria, significantly reducing infection rates and the risk of viral infections such as including RSV, influenza, and rhinovirus, compared to physiological saline. Additionally, probiotics have shown the ability to regulate immunity, strengthening respiratory defenses and significantly reduce the rate of children needing to miss school or take antibiotics, anti-inflammatory drugs, etc.

The study received an “Excellent”  by the evaluation committee due to its high applicability and safety for children. LiveSpo^® NAVAX promises to become a potential solution in preventing respiratory tract infections, especially during the changing seasons, helping to minimize dependence on antibiotics in the treatment of respiratory infections in children.

Four staff members from the Spobio Research Center, ANABIO R&D Ltd, represented the company at the 27th National Scientific Conference on Otolaryngology & Head and Neck Surgery, held from November 1^st to 3^rd, 2024, in Ninh Binh City, Ninh Binh Province. This prestigious event attracted numerous leading experts, doctors, and pharmacists from both domestic and international communities to discuss, share, and update each other on prominent advancements in the field of Otolaryngology.

At the conference, Assoc. Prof. Dr. MD. Pham Tran Anh, who works at the Central Otolaryngology Hospital and is also a lecturer at the Department of Otolaryngology, Hanoi Medical University, presented a report titled “Effectiveness of Nasal-spraying Bacillus Spores in Preventing Respiratory Tract Infections in Children: Results from the Community Intervention Study 2023-2024.” This report is part of a scientific project in collaboration with the Institute of Preventive Medicine and Public Health, Hanoi Medical University, and the Spobio Research Center, ANABIO R&D Ltd. The report highlighted the safety and superior efficacy of the LiveSpo^® NAVAX and LiveSpo^® NAVAX KIDS products in protecting children’s respiratory health. Specifically, LiveSpo^® NAVAX significantly reduced the incidence of typical respiratory infection symptoms such as runny nose, sinusitis, hoarseness, sore throat, and tonsillitis by up to 60% after 14 and 28 days of use. Furthermore, the rate of children missing school due to illness and the use of antibiotics and anti-inflammatory medications also showed a significant decrease. Notably, LiveSpo^® NAVAX and LiveSpo^® NAVAX KIDS helped reduce the rate of bacterial infections by up to 70% and decreased the risk of viral infections such as RSV and influenza by more than 11 folds, showing superior results compared to the use of saline solution.

The study results present new opportunities for using Bacillus spores to prevent respiratory diseases in children, especially during seasonal changes. The report by Assoc. Prof. Dr. MD. Pham Tran Anh received considerable attention and high praise from leading experts and doctors in the field of Otolaryngology.

Outside of the report sessions, the booth showcasing LiveSpo^® NAVAX and LiveSpo^® NAVAX KIDS also drew considerable attention from experts and doctors. Delegates expressed special interest in the effectiveness of these products in preventing respiratory diseases in children.

On September 11, 2024, at the National Institute of Nutrition, the research team from the National Institute of Nutrition and the Probiotic Spore Research Center – ANABIO R&D Co., Ltd., successfully completed the research project titled: Evaluation of the Effectiveness of LiveSpo® PREG-MOM and LiveSpo® KIDS Products in Supporting the Reduction of Constipation, Anorexia, and Slow Weight Gain in Children Aged 24-60 Months, led by Dr. Nguyen Thi Luong Hanh from the National Institute of Nutrition.

The study was conducted from October 2023 to October 2024 on children with constipation and poor appetite. The results showed remarkable improvements after using the products, including:

• A reduction in the rate of poor appetite and constipation among children in the LiveSpo® PREG-MOM and LiveSpo® KIDS groups, with significantly better outcomes compared to the control group.
• Improved nutritional status, reducing the risk of mild malnutrition in children using LiveSpo® PREG-MOM and LiveSpo® KIDS.
• Enhanced immunity for children.
• A significant increase in beneficial bacteria, a reduction in harmful bacteria, and an improvement in the gut microbiota.

The study’s findings provide critical scientific evidence supporting the effectiveness of LiveSpo® PREG-MOM and LiveSpo® KIDS in improving digestive health and enhancing overall health in young children

On September 21, 2024, the ANABIO Spobiotic Research Center (ANABIO R&D) had the honor of welcoming Mr. Lukasz – an investor from Mekong Capital – to visit its Center.

During the visit, Mr. Lukasz was briefed by the R&D specialists at the Center on the research and development processes, as well as the outstanding efficacy of the probiotic products currently in development. These results, validated through clinical trials, not only confirm the quality of the products but also stand as evidence of the company’s commitment to delivering breakthrough, reliable health solutions.

Mr. Lukasz highly appreciated the efforts and achievements of the Center’s staff, and expressed strong confidence in the company’s potential to shape the probiotic market in Vietnam. He also offered strategic recommendations for upgrading infrastructure and expanding the research center to position the company as an internationally recognized biotech enterprise. According to Mr. Lukasz, with its bold direction and long-term vision, the company has the potential to become a “tech unicorn” – directly competing with the world’s leading bioproduct corporations. Mr. Lukasz’s visit underscores the company’s growing appeal on the international stage and provides strong motivation for continued investment in research and development. This support reinforces the company’s mission to elevate the LiveSpo brand of probiotics globally, accompanying consumers worldwide on their journey toward comprehensive health protection

Here are a few images from the visit: